1. Home
  2. AUPH vs LGIH Comparison

AUPH vs LGIH Comparison

Compare AUPH & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • LGIH
  • Stock Information
  • Founded
  • AUPH 1993
  • LGIH 2003
  • Country
  • AUPH Canada
  • LGIH United States
  • Employees
  • AUPH 300
  • LGIH N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • LGIH Homebuilding
  • Sector
  • AUPH Health Care
  • LGIH Consumer Discretionary
  • Exchange
  • AUPH Nasdaq
  • LGIH Nasdaq
  • Market Cap
  • AUPH 1.2B
  • LGIH 1.2B
  • IPO Year
  • AUPH 1999
  • LGIH 2013
  • Fundamental
  • Price
  • AUPH $8.93
  • LGIH $57.58
  • Analyst Decision
  • AUPH Strong Buy
  • LGIH Hold
  • Analyst Count
  • AUPH 2
  • LGIH 5
  • Target Price
  • AUPH $11.50
  • LGIH $84.00
  • AVG Volume (30 Days)
  • AUPH 2.1M
  • LGIH 398.7K
  • Earning Date
  • AUPH 07-31-2025
  • LGIH 08-05-2025
  • Dividend Yield
  • AUPH N/A
  • LGIH N/A
  • EPS Growth
  • AUPH N/A
  • LGIH N/A
  • EPS
  • AUPH 0.27
  • LGIH 7.76
  • Revenue
  • AUPH $247,295,000.00
  • LGIH $2,163,167,000.00
  • Revenue This Year
  • AUPH $12.15
  • LGIH N/A
  • Revenue Next Year
  • AUPH $18.34
  • LGIH $27.68
  • P/E Ratio
  • AUPH $33.57
  • LGIH $7.42
  • Revenue Growth
  • AUPH 29.20
  • LGIH N/A
  • 52 Week Low
  • AUPH $5.20
  • LGIH $47.17
  • 52 Week High
  • AUPH $10.67
  • LGIH $125.83
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 57.25
  • LGIH 57.79
  • Support Level
  • AUPH $8.73
  • LGIH $50.36
  • Resistance Level
  • AUPH $9.37
  • LGIH $61.02
  • Average True Range (ATR)
  • AUPH 0.41
  • LGIH 2.72
  • MACD
  • AUPH 0.04
  • LGIH 0.62
  • Stochastic Oscillator
  • AUPH 77.28
  • LGIH 68.61

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. They have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.

Share on Social Networks: